|
gptkbp:instanceOf
|
gptkb:substance_abuse
gptkb:alkaloid
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
83-74-9
|
|
gptkbp:category
|
gptkb:alkaloid
psychedelic
anti-addictive agent
plant alkaloid
|
|
gptkbp:chemicalFormula
|
C20H26N2O
|
|
gptkbp:color
|
white (crystalline powder)
|
|
gptkbp:discoveredBy
|
gptkb:Dybowski_and_Landrin
|
|
gptkbp:discoveredIn
|
1901
|
|
gptkbp:foundIn
|
gptkb:Tabernanthe_iboga
|
|
gptkbp:IUPACName
|
gptkb:12-methoxyibogamine
|
|
gptkbp:legalStatus
|
gptkb:Schedule_I_(United_States)
controlled substance (various countries)
|
|
gptkbp:mechanismOfAction
|
gptkb:norepinephrine_reuptake_inhibitor
gptkb:NMDA_receptor_antagonist
kappa-opioid receptor agonist
|
|
gptkbp:meltingPoint
|
152°C
|
|
gptkbp:metabolism
|
gptkb:noribogaine
|
|
gptkbp:molecularWeight
|
310.44 g/mol
|
|
gptkbp:origin
|
gptkb:Central_Africa
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL12313
197060
|
|
gptkbp:riskFactor
|
QT prolongation
sudden cardiac death
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
ataxia
hallucinations
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in alcohol
|
|
gptkbp:traditionalUse
|
gptkb:Bwiti_religion
|
|
gptkbp:UNII
|
7B1Q1F2M1V
|
|
gptkbp:usedFor
|
addiction treatment
|
|
gptkbp:bfsParent
|
gptkb:MAPS
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ibogaine
|